-

12:02:36 PM

CHRS Stock News

CHRS - Coherus Biosciences Inc

01/10/22 7:30 AM

Nasdaq : CHRS

Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

• Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types • Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy REDWOOD CITY, Calif., and

RHEA-AI

positive

01/07/22 8:30 AM

Nasdaq : CHRS

Coherus BioSciences Secures Credit Financing with Pharmakon Advisors

Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) today announced that it has entered into a loan agreement

RHEA-AI

positive

01/04/22 8:32 AM

Nasdaq : CHRS

conferences

Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9 a.m. EST / 6 a.m. PST. The audio portion

RHEA-AI

neutral

12/20/21 7:59 AM

Nasdaq : CHRS

fda approval

Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)

Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the

RHEA-AI

very positive

12/17/21 9:09 AM

Nasdaq : CHRS

management

Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer

Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Theresa LaVallee, Ph.D. as its Chief Development Officer. Dr. LaVallee will serve as a member of the Company’s executive leadership team and oversee all regulatory

RHEA-AI

neutral

12/16/21 4:30 PM

Nasdaq : CHRS

Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Dec. 13, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 367,000 shares of

RHEA-AI

very positive

12/13/21 7:00 AM

Nasdaq : CHRS

clinical trial

Coherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences,

RHEA-AI

positive

11/15/21 8:30 AM

Nasdaq : CHRS

Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has

RHEA-AI

very positive

11/10/21 4:15 PM

Nasdaq : CHRS

Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Nov. 5, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 177,500 shares of

RHEA-AI

very positive

11/08/21 4:01 PM

Nasdaq : CHRS

Coherus BioSciences Reports Third Quarter 2021 Results

– Key milestones achieved driving near-term commercial product portfolio expansion – – Three BLAs now under FDA review: PD-1 inhibitor toripalimab, biosimilar Lucentis®, biosimilar Humira® – – Multiple additional applications to FDA expected in 2022 – – UDENYCA® delivers 3rd quarter 2021 net sales

RHEA-AI

positive

1 2 3 4 5 6 7 Next